Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 jun 2009 - 16:42
Statutaire naam
Crucell N.V.
Titel
Crucell 2009 Annual General Meeting of Shareholders 2008 Financial Statements Adopted; All Resolutions Approved
Bericht
Leiden, The Netherlands (June 5, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the Annual General Meeting of Shareholders (AGM) held today in Leiden adopted the 2008 financial statements. In addition, the AGM reappointed Mr. P. Satow and Mr. A. Hoevenaars as members of the Supervisory Board; Mr. Floris Waller was appointed as a new member of the Supervisory Board.
The shareholders of Crucell were represented in person, by proxy voting, or by voting instruction, representing a total of 27% of the total issued share capital entitled to vote.
The shareholders approved the appointment of Mr. Floris Waller as a member of the Supervisory Board. The appointment is for a term of four years, until 2013. Other members of the Supervisory Board, Mr. Philip Satow and Mr. Arnold Hoevenaars, were reappointed for a term of four years by Crucell’s shareholders.
Furthermore the AGM approved the 2008 financial statements and all other resolutions.
At the meeting, presided by Jan Oosterveld, Chairman of the Supervisory Board, Ronald Brus, CEO of Crucell and Leon Kruimer, CFO discussed the company’s 2008 results, reiterated the outlook for 2009 , and presented their views on the business and strategy of the company to shareholders. The slides of the presentation given at the AGM are available on the company’s website www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 22, 2009, in the section entitled ‘Risk Factors’. The Company prepares its financial statements under International Financial Reporting Standards (IFRS).
Datum laatste update: 23 december 2025